5 Top Losers In Healthcare Sector (ZFGN, TNXP, ENZ…)

The following are some of the pharma/biotech stocks that posted the biggest percentage decline today. 1. Zafgen Inc. (ZFGN) Lost 37.17% to close Tuesday’s (Mar.12) trading at $2.89. News: The Company has suspended its plans to file an investigational new drug application for ZGN-1258, a candidate for rare metabolic disorders including Prader-Willi syndrome. The decision to suspend the development of […]

Read more

ATOS Skyrockets, BPMX Gets "Going Concern" Warning, Respite For KPTI

Today’s Daily Dose brings you news about the positive progress of Atossa Genetics’ Oral Endoxifen as a post-mastectomy treatment for breast cancer; BioLife Solutions’ stellar fourth-quarter financial results; BioPharmX Corp’s anticipated milestones in 2019; revised FDA decision date of Karyopharm’s Selinexor; and clinical trial catalysts of SCYNEXIS. Read on… Shares of Atossa Genetics Inc. (ATOS) jumped more than 350% on […]

Read more

After Gottlieb, FDA must stop dragging feet on less risky alternatives to cigarettes

FDA threatens to pull e-cigarettes off store shelves Fox News medical correspondent Dr. Marc Siegel on mounting concerns over youth e-cigarette use. For outgoing Food and Drug Administration (FDA) Commissioner Scott Gottlieb’s replacement, President Trump should nominate a commissioner who will work quickly to help smokers switch to less harmful tobacco products. Continue Reading Below For the past 10 years, the […]

Read more

Alnylam: Givosiran Meets Primary, Majority Secondary Endpoints In Envision Study

Alnylam Pharmaceuticals, Inc. (ALNY) said Wednesday that the ENVISION Phase 3 study of givosiran met its primary efficacy endpoint and the majority of secondary endpoints. Givosiran is an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) in development for the treatment of acute hepatic porphyria or AHP. Specifically, givosiran met the primary endpoint of reduction in the annualized rate […]

Read more

Trump's FDA chief resigns as admin pushes forward on drug pricing plan

Trump FDA generic drug approval cuts health cost by increasing competition: Kevin Hassett White House Council of Economic Advisors Chairman Kevin Hassett weighs in on the looming government shutdown threat, China trade talks, the economy and health care. Scott Gottlieb, President Trump's head of the Food and Drug Administration, resigned from his post on Tuesday and is expected to depart […]

Read more

FDA Nod For NVO’s Hemophilia A Drug, ICPT’s NASH Trial Hits Goal, NVTA Abuzz

Today’s Daily Dose brings you news about Bausch Health’s acquisition of the U.S. rights to Eton Pharma’s EM-100 eye drop; Cellular Biomedicine’s business highlights and financial results for Q4, 2018; CE Mark approval for Edwards Lifesciences’ PASCAL transcatheter valve repair system; Invitae’s better-than-expected Q4 financial results; positive results of Intec Pharma’s (NTEC) pharmacokinetic study of Accordion Pill in Parkinson’s disease […]

Read more

7 Top Gainers In Healthcare Sector (PTX, MYOV, DXR…)

The following are some of today’s top gainers in the pharma/biotech sector. 1. Pernix Therapeutics Holdings Inc. (PTX) Pernix Therapeutics Holdings is the parent company of Pernix Therapeutics LLC, a specialty pharmaceutical business focused on acquiring and commercializing prescription drugs, primarily for the U.S. market. Gained 54.24% to close Wednesday’s (Feb.13) trading at $1.82. News: No news Recent event: On […]

Read more

FDA Nod For NVO’s Hemophilia A Drug, ICPT’s NASH Trial Hits Goal, NVTA Abuzz

Today’s Daily Dose brings you news about Bausch Health’s acquisition of the U.S. rights to Eton Pharma’s EM-100 eye drop; Cellular Biomedicine’s business highlights and financial results for Q4, 2018; CE Mark approval for Edwards Lifesciences’ PASCAL transcatheter valve repair system; Invitae’s better-than-expected Q4 financial results; positive results of Intec Pharma’s (NTEC) pharmacokinetic study of Accordion Pill in Parkinson’s disease […]

Read more

5 Top Gainers In Healthcare Sector (CASM, VKTX, ADMA…)

The following are some of today’s top gainers in the pharma/biotech sector. 1. CAS Medical Systems Inc. (CASM) Gained 54.14% to close Tuesday’s (Feb.12) trading at $2.42. News: The Company is all set to be acquired by Edwards Lifesciences Corporation (EW) in an all-cash transaction for $2.45 per share of Common Stock, or an equity value of approximately $100 million. […]

Read more
1 2 3 12